Table 1.
Cohort Characteristics
| Cohort (n = 473) | COPD (n = 351) | ILD (n = 122) | P-Value | |
|---|---|---|---|---|
| Demographics | ||||
| Age at evaluation (years) | 59 (54–63) | 58 (53–62) | 61 (55–66) | .0002 |
| Male sex (%) | 47% | 42% | 61% | <.001 |
| Caucasian race (%) | 82% | 86% | 72% | <.001 |
| BMI | 26 (22–30) | 25 (22–30) | 29 (25–32) | .009 |
| Diabetes mellitus | 20% | 14% | 40% | <.001 |
| Hypertension | 52% | 50% | 55% | .33 |
| Hyperlipidemia | 28% | 26% | 35% | .04 |
| Tobacco exposure (pack-years) | 40 (25–70) | 50 (35–75) | 15 (0–35) | <.0001 |
| Supplemental oxygen (%) | 89% | 89% | 86% | .40 |
| CAD clinical diagnosis | 13% | 10% | 20% | .007 |
| Lipid values | ||||
| Total cholesterol (mg/dL) | 200 (165–234) | 206 (178–243) | 176 (147–215) | <.0001 |
| Triglycerides (mg/dL) | 103 (70–148) | 93 (67–142) | 117 (83–160) | .002 |
| HDL-C (mg/dL) | 62 (47–79) | 69 (53–84) | 49 (39–60) | <.0001 |
| LDL-C (mg/dL) | 110 (84–137) | 114 (86–142) | 100 (80–131) | .009 |
| TC/HDL-C | 3.1 (2.5–4.0) | 2.9 (2.4–3.8) | 3.7 (2.7–4.7) | <.0001 |
| Medications | ||||
| Statin | 29% | 24% | 42% | <.001 |
| Beta-blocker | 10% | 5% | 21% | <.001 |
| Calcium channel blocker | 24% | 26% | 20% | .20 |
| ACE inhibitor or ARB | 23% | 22% | 26% | .45 |
| Aspirin | 23% | 20% | 32% | 0.008 |
| Clopidogrel | 3% | 1% | 7% | 0.003 |
ACE = angiotensin-converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; HDL-C = high-density lipoprotein cholesterol; ILD = interstitial lung disease; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol.
Data are expressed as medians (interquartile ranges) or as percentages. P values were obtained through Wilcoxon rank sum, chi-squared, or Fisher’s exact tests as appropriate, and refer to comparison between COPD and ILD subgroups.